| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.09 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.084 | 0.09 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.064 | 0.09 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.068 | 0.09 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.09 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.09 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.09 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.1 |